These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12706360)

  • 1. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
    Eskens FA; Dumez H; Hoekstra R; Perschl A; Brindley C; Böttcher S; Wynendaele W; Drevs J; Verweij J; van Oosterom AT
    Eur J Cancer; 2003 May; 39(7):917-26. PubMed ID: 12706360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.
    Haddad T; Qin R; Lupu R; Satele D; Eadens M; Goetz MP; Erlichman C; Molina J
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1221-1227. PubMed ID: 28477227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of continuous infusion cilengitide in patients with solid tumors.
    O'Donnell PH; Undevia SD; Stadler WM; Karrison TM; Nicholas MK; Janisch L; Ratain MJ
    Invest New Drugs; 2012 Apr; 30(2):604-10. PubMed ID: 20839028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.
    Massabeau C; Khalifa J; Filleron T; Modesto A; Bigay-Gamé L; Plat G; Dierickx L; Aziza R; Rouquette I; Gomez-Roca C; Mounier M; Delord JP; Toulas C; Olivier P; Chatelut E; Mazières J; Cohen-Jonathan Moyal E
    Clin Lung Cancer; 2018 May; 19(3):e277-e285. PubMed ID: 29221762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
    Hariharan S; Gustafson D; Holden S; McConkey D; Davis D; Morrow M; Basche M; Gore L; Zang C; O'Bryant CL; Baron A; Gallemann D; Colevas D; Eckhardt SG
    Ann Oncol; 2007 Aug; 18(8):1400-7. PubMed ID: 17693653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.
    Alva A; Slovin S; Daignault S; Carducci M; Dipaola R; Pienta K; Agus D; Cooney K; Chen A; Smith DC; Hussain M
    Invest New Drugs; 2012 Apr; 30(2):749-57. PubMed ID: 21049281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.
    Becker A; von Richter O; Kovar A; Scheible H; van Lier JJ; Johne A
    J Clin Pharmacol; 2015 Jul; 55(7):815-24. PubMed ID: 25683324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.
    Manegold C; Vansteenkiste J; Cardenal F; Schuette W; Woll PJ; Ulsperger E; Kerber A; Eckmayr J; von Pawel J
    Invest New Drugs; 2013 Feb; 31(1):175-82. PubMed ID: 22752690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.
    MacDonald TJ; Stewart CF; Kocak M; Goldman S; Ellenbogen RG; Phillips P; Lafond D; Poussaint TY; Kieran MW; Boyett JM; Kun LE
    J Clin Oncol; 2008 Feb; 26(6):919-24. PubMed ID: 18281665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.
    Kim KB; Prieto V; Joseph RW; Diwan AH; Gallick GE; Papadopoulos NE; Bedikian AY; Camacho LH; Hwu P; Ng CS; Wei W; Johnson MM; Wittemer SM; Vardeleon A; Reckeweg A; Colevas AD
    Melanoma Res; 2012 Aug; 22(4):294-301. PubMed ID: 22668797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
    Leblond P; Meignan S; Le Tinier F; Bethe U; Lansiaux A
    Bull Cancer; 2011 Oct; 98(9):1083-90. PubMed ID: 21914576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
    Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
    Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.
    Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B
    Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
    Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
    Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrins as target: first phase III trial launches, but questions remain.
    Carter A
    J Natl Cancer Inst; 2010 May; 102(10):675-7. PubMed ID: 20460633
    [No Abstract]   [Full Text] [Related]  

  • 16. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
    Reardon DA; Nabors LB; Stupp R; Mikkelsen T
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1225-35. PubMed ID: 18616418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
    Beekman KW; Colevas AD; Cooney K; Dipaola R; Dunn RL; Gross M; Keller ET; Pienta KJ; Ryan CJ; Smith D; Hussain M
    Clin Genitourin Cancer; 2006 Mar; 4(4):299-302. PubMed ID: 16729916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
    Cheng NC; van Zandwijk N; Reid G
    PLoS One; 2014; 9(3):e90374. PubMed ID: 24595274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
    O'Donnell PH; Karovic S; Karrison TG; Janisch L; Levine MR; Harris PJ; Polite BN; Cohen EE; Fleming GF; Ratain MJ; Maitland ML
    Clin Cancer Res; 2015 Nov; 21(22):5092-9. PubMed ID: 26199386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.